Previous Close | 93.55 |
Open | 93.59 |
Bid | 93.38 x 800 |
Ask | 93.50 x 1100 |
Day's Range | 93.40 - 94.92 |
52 Week Range | 70.89 - 94.92 |
Volume | |
Avg. Volume | 11,493,221 |
Market Cap | 237.278B |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | 16.79 |
EPS (TTM) | 5.59 |
Earnings Date | Jul 28, 2022 |
Forward Dividend & Yield | 2.76 (2.95%) |
Ex-Dividend Date | Mar 14, 2022 |
1y Target Est | 96.06 |
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Rates could spike sooner rather than later. Prepare your portfolio.